Trade the Fresenius share!

Analysis before buying or selling Fresenius shares

Trade the Fresenius share!

Your capital is at risk
Chart provided by Tradingview

Dividend payments
Can I receive dividends when I buy Fresenius shares?
Information on Fresenius shares
ISIN code: DE0005785604
Ticker: ETR: FRE
Index or market: DAX

How to buy and sell Fresenius shares with eToro?

Open an account by clicking here
Deposit Funds
Search Fresenius (ETR: FRE)
Buy/Sell Fresenius shares
Your capital is at risk

Elements to consider before selling or buying Fresenius shares

Analysis N°1

In particular, the merger or acquisition operations carried out by the Fresenius Group should be analysed and represent interesting development opportunities.

Analysis N°2

The pricing strategies that tend to evolve over time at Fresenius will also be important in the context of the group's overall development strategy.

Analysis N°3

Of course, the investments in research and development made by the group will have to be important and relevant in your fundamental analysis because Fresenius needs constant innovation in order to maintain a good position against the competition.

Analysis N°4

We will also keep an eye on government regulations and political risks that may threaten Fresenius' profitability in certain countries. Any changes in these regulations will therefore be closely monitored.

Analysis N°5

Finally, the competition and the development of the market shares of each major player in this business sector will be closely monitored for the threat it poses to Fresenius in the long term.

Analysis before buying or selling Fresenius shares
Buy Fresenius shares
Sell Fresenius shares
Your capital is at risk

General presentation of Fresenius

Buy Fresenius shares

The German Fresenius Group is a specialist in the design, manufacture and sale of drugs and medical equipment. The largest part of its turnover is generated by the sale of dialysis treatments, but it also offers hospital administration and engineering, infusion and chemical nutrition systems as well as other products and services.

Fresenius generates most of its profits in North America and Europe.

Photo credits: ©peterbrauers/123RF.COM

The major competitors of Fresenius

We would like to introduce you to the main competitors of the Fresenius Group with an overview of the most important players in the industry today, so that you can focus your industry research and keep track of important information, data and publications.

Johnson & Johnson 

This US pharmaceutical company specialises, inter alia, in the production of pharmaceutical and medical devices as well as hygiene products, cosmetics and related services for consumers and healthcare professionals. It operates 250 subsidiaries in some 60 countries and markets its products in 175 countries.


This company is active in medical technology on an international level. It is based in Ireland and operates several other headquarters in various countries and regions of the world.

General Electric 

GE is an American conglomerate formed by the merger of part of Thomson Houston Electric Company and Edison General Electric Company. It has 36 subsidiaries in more than 150 countries and is listed on the NYSE, where it has long been among the largest market capitalizations.


This international German group specialises in the energy, health, industry and construction sectors and is based in Munich. It is currently the country's largest private employer and the largest engineering company in Europe.


The Philips Group is a Dutch technology company and a leader in household appliances, medical equipment and lighting. It employs 114,000 people in about 100 countries.

Becton Dickinson and Company 

Finally, this American company specialises in the production and sale of medical equipment. It is present in about fifty countries and employs more than 70,000 people. The company is known for being one of the first to market syringes in the United States and was also a pioneer in the production of hypodermic needles. Its business is now divided into three segments with BD Medical, BD Diagnostics and BD Biosciences.

The major partners of Fresenius

To conclude this article, we would like to introduce you to the most important partnerships that Fresenius has established over the past few years.

CyoSorbents Corporation

In 2014, Fresenius partnered with CytoSorbents Corporation, the world's leading provider of immunotherapy for critical care and blood purification in a strategic multinational agreement to commercialize CytoSorb therapy developed by CytoSorbents.


In 2015, the Fresenius Kabi subsidiary signed a partnership agreement with the Phelma education group to strengthen its courses.


More recently, in 2017, Fresenius acquired the Biosimilars business of Merck Laboratories for €670 million.

Trade the Fresenius share!
Your capital is at risk. Performance is not a guide to future performance and is not constant over time.
Positive factors for Fresenius shares
The factors in favour of a rise in the Fresenius share price:

First of all, Fresenius has achieved success through its long history and high level of experience in the field of services and innovation. This gives the company a clear advantage over the competition and helps to reassure its customers and build up their loyalty quickly and sustainably.

The positioning of the German Fresenius Group in its core business is of course another of its strengths that must be taken into account here. Fresenius is the market leader in its segment and has been for several years, far ahead of its main competitors.

The group also benefits from excellent vertical integration.

Of course, Fresenius has been able to rely on a number of strengths to become the number one in its sector, including the quality and qualifications of its staff, its experience and also its financial strengths. It has a strong cash flow and very good results.

In terms of the benefits of Fresenius, it is noted that it has excellent relationships with hospitals. This adds value to its brand image and earns the trust of other customers.

Finally, the geographical positioning of the Fresenius company is also a strong point. The group has a strong international presence and is active in more than 100 different countries around the world.

Negative factors for Fresenius shares
The factors in favour of a drop in the Fresenius share price:

Fresenius may be attractive to many investors because of its many strengths, but there are a few weaknesses that can affect the company's long-term profitability and hinder its growth. In reality, there are only two major weaknesses to this company, which you should nevertheless be aware of.

First of all, we note that the group would need to increase its production and manufacturing power. It is indeed competing with some giants of this industry on a global scale who are better able to respond efficiently and quickly to the demand thanks to a much larger production force.

Finally, the second weakness of Fresenius is that it is highly dependent on the exchange rates prevailing on the foreign exchange market. This means that its costs and profits can be influenced by changes in the exchange rates of the currencies in which it pays its suppliers or invoices its international customers.

The information supplied here is only for indicative purposes and should not be used without the completion of a comprehensive and complete fundamental analysis of this asset notably taking into account exterior data, future publications and announcements and all fundamental events and news that could influence the strengths and weaknesses or make them more or less significant. This information does not in any way constitute recommendations relating to the completion of transactions or a solicitation to buy or sell an asset.
Trade the Fresenius share!

eToro is a multi-asset platform which offers both investing in stocks and cryptoassets, as well as trading CFDs.

Please note that CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. {etoroCFDrisk}% of retail CFD accounts lose money. You should consider whether you can afford to take the high risk of losing your money.

Past performance is not an indication of future results. Trading history presented is less than 5 complete years and may not suffice as basis for investment decision.

Copy trading is a portfolio management service, provided by eToro (Europe) Ltd., which is authorised and regulated by the Cyprus Securities and Exchange Commission.

Cryptoasset investing is unregulated in some EU countries and the UK. No consumer protection. Your capital is at risk.

eToro USA LLC does not offer CFDs and makes no representation and assumes no liability as to the accuracy or completeness of the content of this publication, which has been prepared by our partner utilizing publicly available non-entity specific information about eToro.